ClinicalTrials.gg
WithdrawnNCT02587572SIRONAUpdated Feb 16, 2023

Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial

A Phase 2 interventional study of Peripheral Intravenous (IV) infusion of LMSCs in Metabolic Disease and Endothelial Dysfunction, sponsored by Longeveron Inc.. Withdrawn. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-02-16.

Sponsored by Longeveron Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor has made decision not to conduct this clinical trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Study summary

This is a phase 2b, randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on endothelial function using several different doses.

Read the detailed description

This is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on endothelial function using several different doses. Following a successful run-in phase, a total of forty (40) subjects will be randomized (1:1:1:1) to receive one of three different doses of LMSCs or placebo. After randomization, baseline imaging, testing and study product infusion, subjects will be followed up at 24 hours, month 1, month 3, month 6, month 9 and month 12 post study product infusion. All endpoints will be assessed at the 3, 6 and 12 month visits which will occur 90±30 days, 180±30 days, and 365±30 days respectively from the day of the study product infusion (Day 1). For the purposes of the endpoint analysis and safety evaluations, an "intent-to-treat" study population will be utilized.

02

Conditions studied

  • Metabolic Disease
  • Endothelial Dysfunction

Browse trials for

03

In context

Metabolic Diseases

763 studies on the registry are indexed under Metabolic Diseases; 192 are open to participants now.

Browse Metabolic Diseases studies →

Lead sponsor

Longeveron Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Each subject must provide written .
  • Each subject must be ≥45 and ≤ 85 years of age at the time of signing the Informed Consent Form.
  • Each subject must have endothelial dysfunction.
  • At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following

    • Hypertension.
    • Elevated triglycerides.
    • Reduced high-density lipoprotein (HDL) levels.
    • Elevated fasting glucose. --Central obesity.

Exclusion criteria

Exclusion Criteria:

  • Be unable and/or unwilling to perform any of the assessments required for endpoint analysis.
  • Have diabetic retinopathy.
  • Sitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening.
  • Have a resting blood oxygen saturation of \<93% (measured by pulse oximetry).
  • Be hypersensitive to dimethyl sulfoxide (DMSO).
  • Have a history of alcohol or drug abuse within the past 24 months.
  • Have been diagnosed with within the past 5 years, with the exception of curatively-treated basal cell carcinoma, melanoma in situ or cervical carcinoma.
  • Be an organ transplant recipient.
  • Be actively listed (or expected to be listed) for transplant of any organ.
  • Have a condition that limits to \< 1 year.
  • Be serum positive for , sAG or viremic .
  • Be a female who is pregnant, nursing, or of while not practicing effective (female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection).
  • Have any serious comorbid illness or other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
  • Be currently participating in an therapeutic or device trial.
  • Be currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that he or she is actively participating in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LMSCs 10 million IV

    A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10\^6 (10 million) of LMSCs to be administered on day 1.

    Biological: Peripheral Intravenous (IV) infusion of LMSCs

  • Placebo comparator
    Placebo (Plasmalyte A,HSA) IV

    10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.

    Biological: Peripheral Intravenous (IV) infusion of LMSCs

  • Experimental
    LMSCs 20 million IV

    10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10\^6 (20 million) LMSCs to be administered on day 1.

    Biological: Peripheral Intravenous (IV) infusion of LMSCs

  • Experimental
    LMSCs100 million IV

    10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10\^6 (100 million) LMSCs to be administered on day 1.

    Biological: Peripheral Intravenous (IV) infusion of LMSCs

Interventions

06

What researchers measure

Primary outcomes

  1. Endothelial function: Changes in endothelial function as assessed by the following:

    Flow-mediated vasodilation (FMD). Endothelial progenitor cell (EPC) function.

    Time frame: 1 month post infusion

Secondary outcomes

  1. Difference in rate of change in the metabolic syndrome as defined by the following:

    Endothelial function (FMD, EPC function) Inflammatory markers (CBC with differential, TNFα, CRP, IL-1, IL-6, D-dimer, Fibrinogen) Heart function and structure (Dobutamine Stress Echocardiography) Blood pressure Lipid profile (HDL; LDL; triglycerides; cholesterol) Physical activity (6 minute walk test and CHAMPS questionnaire) Lung function (spirometry) Glycemia (hemoglobin A1c;fasting glucose; urine glucose) Weight Subject quality of life (QOL) (QOL assessments).

    Time frame: Baseline, 3 month, 6 month and 12 months.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2023; primary completion for Dec 2023, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2015
First posted
Oct 27, 2015
StartEst.
Dec 1, 2023
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Feb 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02587572
Lead sponsor
Longeveron Inc.
Responsible party
Sponsor
First posted
Oct 27, 2015
Start date
Dec 1, 2023 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Feb 16, 2023

Study contacts

Anthony Oliva, PhD
study director · Longeveron Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Biological Products

Start the discussion